Source comparison
CJC-1295 no DAC & Ipamorelin vs Ipamorelin — Real Peptides
Research from the Journal of Clinical Endocrinology & Metabolism found that growth hormone pulse amplitude matters less than total GH exposure time when evaluating downstream anabolic signaling. Ipamorelin generates a sharp GH spike. CJC-1295 no DAC (also call
This comparison does not assign a generated winner or score.
- Research from the Journal of Clinical Endocrinology & Metabolism found that growth hormone pulse amplitude matters less than total GH exposure time when evaluating downstream anabolic signaling. Ipamorelin generates a sharp GH spike. CJC-1295 no DAC (also called Modified GRF 1-29) extends that spike from 90 minutes to 3+ hours, tripling the window for IGF-1 production and tissue-level receptor activation.
- We've supplied both compounds independently and as blended formulations to research institutions since 2018. The difference between running Ipamorelin solo and pairing it with CJC-1295 no DAC isn't just additive. It's mechanistically synergistic, and that distinction changes how you interpret study endpoints.
- What is the difference between CJC-1295 no DAC & Ipamorelin vs Ipamorelin alone?
- CJC-1295 no DAC & Ipamorelin combines a GHRH (growth hormone-releasing hormone) analog with a GHRP (growth hormone-releasing peptide) to create dual-pathway GH secretion. CJC-1295 no DAC amplifies natural pulsatile release while Ipamorelin triggers selective ghrelin receptor activation. Ipamorelin alone generates strong but brief GH pulses lasting 90–120 minutes; adding CJC-1295 no DAC extends that duration to 180+ minutes and increases mean GH AUC (area under the curve) by 60–80% without elevating cortisol or prolactin.
- The confusion around CJC-1295 no DAC & Ipamorelin vs Ipamorelin starts with naming conventions. CJC-1295 no DAC is Modified GRF 1-29. Not the same compound as CJC-1295 with DAC (Drug Affinity Complex), which has a half-life of 6–8 days and causes sustained, non-pulsatile GH elevation. The "no DAC" version has a half-life of approximately 30 minutes, preserving the body's natural pulsatile rhythm rather than replacing it. That timing precision is why it pairs so effectively with Ipamorelin. This article covers the receptor-level mechanisms driving the synergy, exact dosing protocols used in research settings, and the specific endpoints where combination therapy outperforms monotherapy.